The Senate Health Committee announced that it will hold a vote on Dr. Heidi Overton's nomination to become FDA commissioner on November 18. While the vote date is set, the outcome of the nomination remains uncertain.
The U.S. Food and Drug Administration has instructed manufacturers of GLP‑1 weight‑loss medications to update their labeling to include a warning about a potential increased risk of a rare eye condition that could lead…
The U.S. Food and Drug Administration says it is amending its food additive petition regulations to update address information and simplify notification procedures. The agency describes the changes as technical and…
In May 2021, the U.S. Food and Drug Administration released a detailed briefing on an experimental medication for a rare autoimmune vasculitis that can affect kidneys and lungs. The agency indicated uncertainty about…
According to the FDA announcement, the agency concluded that LASIX (furosemide) oral solution, 10 mg/mL, was not removed from the market due to safety or effectiveness concerns. Consequently, the FDA will not initiate…
The U.S. Food and Drug Administration has issued a notice stating that it has determined the regulatory review period for the drug MONOFERRIC, as required by law for a pending patent extension application submitted to…
A court filing indicates the Food and Drug Administration will not release its safety review of the abortion medication mifepristone until March and does not plan to impose additional restrictions on the drug before…
The U.S. Food and Drug Administration issued a correction to a May 7, 2026 Federal Register notice, clarifying that approval for 15 abbreviated new drug applications (ANDAs) was withdrawn effective June 8, 2026. The…
According to an FDA statement, the agency has concluded that the pralidoxime chloride autoinjector (600 mg/2 mL) was not removed from the market due to safety or effectiveness concerns, which would permit approval of…
The Food and Drug Administration’s Commissioner has determined that renewing the Antimicrobial Drugs Advisory Committee serves the public interest and has extended its charter for an additional two years beyond the…
The Department of Health and Human Services has announced a new effort to redesign clinical trial processes with the stated goal of reducing development time and costs for new drugs. The announcement, reported by the…
A Government Accountability Office report notes that the criteria used by the DEA and FDA to place substances in controlled‑substance schedules are not clearly defined in the Controlled Substances Act, leading to…
The U.S. Food and Drug Administration has announced a proposal to classify the flushing and storage solution used for vascular autografts kept at room temperature as a Class II medical device, subject to specific…